SCHEMBL5502106

SCHEMBL5502106

Cc1nc2ccccc2c(O[Si](C)(C)C(C)(C)C)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.46
PDE10A Q9Y233 1/20 0.45
POLB P06746 1/20 0.44
ALDH1A1 P00352 2/20 0.42
HSD17B10 Q99714 2/20 0.42
CYP1A2 P05177 1/20 0.42
HPGD P15428 1/20 0.42
NUDT1 P36639 1/20 0.42
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GLA P06280 1/20 0.40
HTT P42858 1/20 0.39
ATM Q13315 1/20 0.38
ELANE P08246 2/20 0.37
DCPS Q96C86 1/20 0.37
TP53 P04637 1/20 0.36
ERN1 O75460 1/20 0.36
CASP3 P42574 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23999688 0.78 POLB (0.68) GPR3PDE10APOLBALDH1A1HSD17B10
SCHEMBL3968650 0.76 GPR3 (0.52) GPR3PDE10APOLBALDH1A1HSD17B10
SCHEMBL4438037 0.74 ALDH1A1 (0.44) POLBALDH1A1CYP1A2KDM4EATM
SCHEMBL5502171 0.74 GFER (0.42) PDE10APOLBALDH1A1HSD17B10CYP1A2
SCHEMBL5502639 0.73 ALDH1A1 (0.43) POLBALDH1A1CYP1A2HPGDKMT2A
SCHEMBL7259506 0.72 GPR3 (0.47) GPR3PDE10APOLBALDH1A1HSD17B10
SCHEMBL1278314 0.71 PDE10A (0.57) GPR3PDE10APOLBALDH1A1HSD17B10
SCHEMBL231530 0.70 GPR3 (0.64) GPR3PDE10APOLBALDH1A1HSD17B10
SCHEMBL6215008 0.70 GPR3 (0.57) GPR3PDE10APOLBALDH1A1HSD17B10
Ammonia Solution, Strong SCHEMBL28822932 0.69 GPR3 (0.61) GPR3PDE10APOLBALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1803150-A1 COMPOUNDS FOR MYOCARDIAL PERFUSION IMAGING Bristol-Myers Squibb Pharma Company (US) 2007-07-04 EP disclosed
WO-2006044280-A1 COMPOUNDS FOR MYOCARDIAL PERFUSION IMAGING BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2006-04-27 WO disclosed
US-20060083681-A1 Compounds for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING, INC. 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060083681-A1 Compounds for myocardial perfusion imaging TNNI3, FABP3, TNNT2 GPR3 921/4885PDE10A 481/4885POLB 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.